Table 4 Compounds that target NLRP3.
From: Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases
Compound | Structure | Clinical stage | Indications | References |
|---|---|---|---|---|
CP-456,773 (MCC950) |
| Phase II-terminated | Rheumatoid arthritis | |
Glyburide |
| Phase IV | Type 2 diabetes | |
Colchicine |
| Phase IV | Gout and FMF | [185] |
OLT1177 |
| Phase II | NA | |
11673-34-0 |
| NA | NA | [101] |
JC-171 |
| NA | NA | [102] |
Fenamate |
| NA | NA | [103] |
CY-09 |
| NA | NA | |
BOT-4-one |
| NA | NA | |
Fclla-2 |
| NA | NA | [109] |
3,4-Methylenedioxy-β-nitrostyrene |
| NA | NA | [110] |
NBC series |
| NA | NA | [111] |
Parthenolide |
| NA | NA | [112] |
BAY 11-7082 |
| NA | NA | |
INF39 |
| NA | NA | [115] |
Spirodalesol |
| NA | NA | [116] |
Oridonin |
| NA | NA | [189] |
